insights_auto
Prečo akcie GNLX klesli 7,94%?
Preskúmať podrobnejšiechevron_right
GNLX:NASDAQ
Genelux Corp
2,32 USD
arrow_downward
-7,94%(-0,20) 1 d.
2,35 USD
arrow_upward
+1,29% (+0,030)bedtimePo uzavretí
Zavreté: 14. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GNLX…
Otvoriť
2,48 USD
Vysoká
2,52 USD
Nízka
2,32 USD
Trh. kap.
104,97 mil.
Priem. obj.
243,39 tis.
Objem
410,41 tis.
Max. za 52 týž.
8,54 USD
Min. za 52 týž.
2,29 USD
Výnosy na akciu
-0,87 USD
Beta
0,59
Akcie v obehu
45,24 mil.
Počet zamestnancov
26
Otvoriť
2,48 USD
Vysoká
2,52 USD
Nízka
2,32 USD
Trh. kap.
104,97 mil.
Priem. obj.
243,39 tis.
Objem
410,41 tis.
Max. za 52 týž.
8,54 USD
Min. za 52 týž.
2,29 USD
Výnosy na akciu
-0,87 USD
Beta
0,59
Akcie v obehu
45,24 mil.
Počet zamestnancov
26
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Yahoo
·
pred 46 minútami
Dow closes in the red after report finds inflation rose in September
GlobeNewswire
·
pred 1 hodinou
Alignment Healthcare (NASDAQ: ALHC) Increasingly
WPTF
·
pred 19 minútami
US stocks drop to their worst day since July as inflation worsens
Investor's Business Daily
·
pred 1 hodinou
Nasdaq, Small Caps Hit On AI Worries, Pesky Inflation: Dell, GILD, THC In Focus
Profil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Informácie o subjekte Genelux Corp
Generálny riaditeľ-
Zamestnanci26
Dátum založenia2001
Hlavné sídloWestlake Village, Kalifornia, Spojené štáty americké
Odvetvie-
Webgenelux.com